An Observational Study of Glofitamab in Chinese Adult Participants With 2L Diffuse Large B-Cell Lymphoma

NCT07200375 · tracked via the Priya Life Science China tracker

Sponsor

Hoffmann-La Roche

Phase

Observational

Started

2025-09-29

Last updated

2026-09-08

Condition(s) studied

Diffuse Large B-Cell Lymphoma

Investigational drug(s) / intervention(s)

Glofitamab →

Glofitamab: Participants will receive glofitamab as part of a cancer-treatment regimen in a real-world setting. No intervention will be administered by study investigators.

Study summary

This study will investigate how well glofitamab-based therapy works and how safe it is in Chinese adult participants with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL).

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * Histologically confirmed R/R DLBCL after one line of systemic therapy * Will be treated with Glofit-based regimen (known as being recommended and having the intention to be treated with Glofitamab at the time of signing ICF) or have initiated Glofit-based regimen treatment within three months (90 days) prior to enrollment Exclusion Criteria: * Participants who currently participate in or plan to participate in any interventional clinical trial

Primary outcome measure(s)

real-world Progression-Free Survival (rwPFS) — Up to approximately 4 years

Trial sites (22)

Facility	City	Region	Status
Cancer Hospital Chinese Academy of Medical Sciences.	Langfang	Hebei	Recruiting
Chinese Academy of Medical Sciences Hematology Hospital;Lymphoma Diagnosis and Treatment Center	Tianjin	Tianjin Municipality	Recruiting
Peking University People's Hospital	Beijing	China	Recruiting
Peking University Third Hospital	Beijing	China	Recruiting
The First Bethune Hospital of Jilin University	Changchun	China	Recruiting
West China Hospital of Sichuan University	Chengdu	China	Recruiting
Guangdong Provincial People's Hospital	Guangzhou	China	Recruiting
Harbin Medical University Cancer Hospital	Harbin	China	Recruiting
Shandong Cancer Hospital	Jinan	China	Recruiting
The Second Affiliated Hospital of Nanchang University	Nanchang	China	Recruiting
The First Affiliated Hospital of Ningbo University	Ningbo	China	Recruiting
Ruijin Hospital, Shanghai Jiaotong University School of Medicine	Shanghai	China	Recruiting
Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine	Shanghai	China	Recruiting
Tianjin Cancer Hospital	Tianjin	China	Recruiting
The First Affiliated Hospital of Wenzhou Medical University	Wenzhou	China	Recruiting
Xiehe Hospital, Tongji Medical College Huazhong University of Science & Technology	Wuhan	China	Recruiting
Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology	Wuhan	China	Recruiting
The First Affiliated Hospital of Xian Jiao Tong University	Xi'an	China	Recruiting
Yantai Yu Huangding Hospital	Yantai	China	Recruiting
Henan Cancer Hospital	Zhengzhou	China	Recruiting
Prince of Wales Hospital	Hong Kong	Hong Kong	Recruiting
Queen Mary Hospital	Hong Kong	Hong Kong	Recruiting

More Hoffmann-La Roche trials in China

A Study of Atezolizumab in High PD-L1 Expression, Chemotherapy-Naïve Patients With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer Active, not recruiting

A Study of Atezolizumab With or Without Tiragolumab Following Neoadjuvant Chemoradiotherapy in Participants With Locally Advanced Rectal Cancer Active, not recruiting

A Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Afimkibart (RO7790121) in Children With Moderately to Severely Active Ulcerative Colitis Recruiting

A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease Active, not recruiting

Real World Clinical Outcomes of Resected ALK-Positive Early Stage NSCLC Patients Treated With Alectinib as Adjuvant Therapy Recruiting

Other trials for the same condition

A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma Active, not recruiting

Metabolic and Immunomic Differential Analysis of Primary Central Nervous System Diffuse Large B-Cell Lymphoma Recruiting

Pola-ZR2P in Previously Untreated DLBCL Recruiting

A Randomized, Open-Label, Multicenter Phase III Clinical Study of JS203 Plus Chemotherapy Versus Rituximab Plus Chemotherapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma Starting soon

Large Fraction Radiation Therapy Combined With Lenalidomide, and Glofitamab in Refractory Relapsed DLBCL Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07200375 on ClinicalTrials.gov ↗ ← All trials in China